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Background: Anaplastic oligodendroglioma (AO) is a type of glioma that is believed to originate from
oligodendrocytes in the brain or from glial precursor cells. Recurrence of AO reduces the overall survival rate of
patients and causes meningeal or even systemic spread/metastasis more frequently than other types of gliomas.
We performed proteomic analysis of recurrent AO tumors to identify the proteins significantly expressed in
recurrent AO and to understand biological characteristics of recurrent AO.
Findings: Using human brain tissues, we identified 401 proteins that were significantly expressed in recurrent AO.
Through bioinformatic analysis, we determined that the majority of the identified proteins are involved in anti-
apoptotic pathway and cell proliferation. In addition, our findings suggest that epidermal growth factor (EGF)
signaling may be responsible for the development of recurrent AO.
Conclusions: These results will aid researchers in understanding the pathology of recurrent AO and identifying the
therapeutic targets for the treatment of recurrent AO.Findings
The goal of proteomics is a comprehensive, quantitative
description of protein expression and its changes under
the influence of biological perturbations such as disease or
drug treatment (Anderson & Anderson 1998; Blackstock
& Weir 1999). Proteins are vital parts of living organisms,
as they are the main components of the physiological
metabolic pathways of cells (James 1997). Recently, a num-
ber of proteomic studies have focused on the metabolic
and signaling pathways associated with the formation and
progression of tumors. The information obtained from
proteomic analysis can be used to identify biomarkers or
therapeutic targets of tumors (Alterovitz et al. 2008).
Anaplastic oligodendroglioma [AO, World Health
Organization (WHO) grade III] is a type of glioma that is
believed to originate from oligodendrocytes in the brain
or from glial precursor cells. AO occurs primarily in
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mors) (Allison et al. 1997). AO is distinguished from other
brain tumors by a unique constellation of molecular gen-
etic alterations, including the coincident loss of chromo-
somal arms 1p and 19q in 50–70% of tumors (Gregory
et al. 1998). AO also has a genetic profile similar to that of
other primary gliomas, such as amplification of epidermal
growth factor receptor (EGFR) expression, 10q loss, p16
deletion, and phosphatase and tensin homolog (PTEN)
mutation without 1p loss or tumor protein 53 (TP53) mu-
tation (Anthony et al. 2003). The standard treatment for
AO is surgical resection followed by radiation and chemo-
therapy with procarbazine, lomustine, and vincristine
(PCV) (Kyritsis et al. 1993; Allison et al. 1997; Cairncross
et al. 1992; Cairncross & Macdonald 1988; Cairncross
et al. 1998; Glass et al. 1992; Kleinberg et al. 1993; Mason
et al. 1996). Despite high response rates (≥ 70%) to treat-
ment, the median survival period is relatively short (Glass
et al. 1992). Accumulation of diverse genetic and epigen-
etic alterations that occur due to interventions for treat-
ment of the tumor may cause extensive changes in the
expression of genes involved in oncogenesis leading to
treatment-related effects such as aggressive transform-
ation (Kleinberg et al. 1993).Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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primary AO, recurrent AO is significantly less well under-
stood. Although a recent study reported the microRNA
expression profile in patients with recurrent AO (Kim
et al. 2011), the biological characteristics of recurrent AO
have never been studied. In this study, we conducted
proteomic analysis of recurrent AO to examine protein
profiles in recurrent AO and identify biological and mo-
lecular characteristics of recurrent AO.
Materials and methods
Patient samples and protein extraction
Institutional Review Board of the Catholic University of
Korea approved of this study. The three specimens were
obtained from patients with recurrent AO treated with
total excision and adjuvant radiotherapy with total dose
of 55.8 Gray (Additional file 1: Table S1) (Kim et al.
2011). The specimens were separated during surgery at
the Seoul St. Mary’s Hospital and stored in liquid nitro-
gen at -80°C.
Protein extraction was conducted previously described
(Cao & Liang 2012) with minor modification. The speci-
mens is added to RIPA buffer (89900, Pierce Biotechnol-
ogy, IL, USA) containing protease inhibitor cocktail
(78410, Pierce), and sonication. Centrifuge 14,000 rpm,
4°C, 20 min, and store supernatant at -80°C. After, the
supernatant was used for SDS-PAGE and LC-MS/MS.
SDS-PAGE and in-gel digestion with trypsin
Protein samples were separated by 12% SDS-PAGE
(mini-PROTEAN, BIO-RAD). A 100 ug of protein sam-
ple was applied to each lane, and the gels were stained
with Coomassie Brilliant Blue R-250. In-gel digestion
was conducted in accordance with the previously de-
scribed method (Kim et al. 2006). Gels were fractionated
into 10 parts according to molecular weight. Each part
was digested with trypsin (1.2 ug) for 16 hours at 37°C
after reduction and alkylation of cysteines of the pro-
teins. Digested peptides were extracted by extraction solu-
tion (50 mM ammonium bicarbonate, 50% acetonitrile,
and 5% trifluoroacetic acid). Digested peptides were re-
solved in 10 ul of sample solution containing 0.02% formic
acid and 0.5% acetic acid, and stored at -80°C until
required.
LC-MS/MS analysis and protein identification
The peptide samples (5 ul) were concentrated on a Easy-
column™ (L 2cm, ID 100um, 120Å, C18-A1) trapping
column (PROXEON, Denmark). Peptides were eluted
from the column and directed onto a Easy-column™
(L 10cm, ID 75um, 120Å, C18-A2) reversephase column
(PROXEON, Denmark) at a flow rate of 200 nl/min.
Peptides were eluted by a gradient of 0~65% acetonitrile
for 120 min. All MS and MS/MS spectra in the LTQ-Velos ESI ion trap mass spectrometer (Thermo Scien-
tific, USA) were acquired in a data-dependent mode.
Each full MS (m/z range of 300 to 2,000) scan was
followed by seven MS/MS scans of the most abundant
precursor ions in the MS spectrum with dynamic exclu-
sion enabled. For protein identification, MS/MS spectra
were searched by MASCOT (Matrix science, www.
matrixscience.com). The proteome sequence database of
IPI human ver. 3.82 (http://www.ebi.ac.uk/IPI) was used
as the database. Mass tolerance of parent ion and frag-
ment ion was 1.5 Da and 1.3 Da, respectively.
Cabamidomethylation of cysteine and oxidation of me-
thionine were considered in MS/MS analysis as variable
modifications of tryptic peptides. Mascot score was
recalculated by percolator function in the mascot for in-
creasing sensitivity of correct identification and false dis-
covery ratios (FDR) of the search results was adjusted to
below 2%.Bioinformatic analysis
Using Ingenuity Pathway Analysis (IPA) tool, all of the
identified proteins in recurrent AO were subjected ana-
lysis of indicated metabolic and signaling pathway. The
identified proteins in recurrent AO were subjected to
query global protein network analysis and direct/in-
direct interactions on proteins that are involved in
pathways associated with epidermal growth factor re-
ceptor (EGFR). For functional enrichment analysis of
Gene Ontology (GO) categories, GOfact online tool
(http://61.50.138.118/gofact) was used. p-value of
Fisher’s exact test determines the probability that the
association between the proteins in the dataset and
the biological function/pathways explained by chance
alone.Results and discussion
Proteomic analysis of recurrent AO
First, we performed proteomics analysis using tumor
sample from patient with recurrent AO who were
treated with postoperative chemoradiotherapy. From
LC-MS/MS, 401 proteins were shown significantly to
express in recurrent AO (Additional file 2: Table S2)
and then we analyzed the 401 identified proteins using
the Ingenuity Pathway Analysis (IPA) tool (http://www.
ingenuity.com). The results revealed the majority of
the metabolically associated proteins that was involved
in biosynthesis of carbohydrates, such as glyoxylate
and dicaboxylate metabolism, oxidative phosphorylation
and glycolysis/gluconeogenesis (Figure 1A). With re-
spect to the signaling pathways active in recurrent AO,
the identified proteins were associated with pathways
responsible for cell growth (Figure 1B). These findings
Figure 1 IPA canonical pathway analysis. Top 15 categories of metabolic pathway (A) and signaling pathway (B) were indicated. The degree
of enrichment or depletion of identified proteins in a given function category is represented as -log(p-value).
Figure 2 Analysis of biological processes of recurrent AO using Gene Ontology (GO) annotation. (A) Distribution of anti-apoptosis and
glial cell apoptosis in recurrent AO. (B) Distribution of cell proliferation, cell adhesion, cell migration and cell differentiation in recurrent AO. The
degree of enrichment or depletion of identified proteins in a given function category is represented as -log(p-value).
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Figure 3 Distribution of signaling pathway associated with cancer. Gene Ontology (GO)-determined signaling pathways associated with
cancer. The degree of enrichment or depletion of identified proteins in a given function category is represented as -log(p-value).
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state of actively growth.
Biological process of recurrent AO
To confirm the biological state of actively growth and dis-
cover the specific cause of recurrent AO, Gene OntologyFigure 4 Proteins related to EGFR in recurrent AO. IPA-determined net
EGFR signaling. Dotted line, indirect; Solid line, direct.(GO) annotation analysis was performed. As shown in
Figure 2A, the results indicated that the identified proteins
were connected to anti-apoptotic functions, while only a few
were associated with glial cell apoptosis. This may indicate
why recurrent AO is resistant to chemoradiotherapy. Anti-
apoptotic effects often contribute to cancer cell survival andwork of identified proteins in the recurrent AO that may be involved in
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18 proteins that are involved in anti-apoptosis pathways are
listed in Additional file 1: Table S3.
Multiple biological processes, including cell prolifera-
tion, adhesion, and migration, have been shown to be in-
volved in tumor development (Lee 1992). Base on our
analyses, the 14 proteins appear to be linked to cell pro-
liferation processes (Figure 2B). Fourteen of these pro-
teins are presented in Additional file 1: Table S4. Tumor
cell is related to cell adhesion and motility. Cell motility
is necessary to moves within tissues during invasion and
metastasis by their own motility (Ymazaki et al. 2005;
Zang et al. 2006). The 11 proteins and 9 proteins ap-
pear to be linked to cell adhesion and migration, re-
spectively (Additional file 1: Table S5 and Table S6).
These findings indicate that the expression of proteins
related to anti-apoptotic and cell proliferation path-
ways are closely related to the development of recurrent
AO. Understanding the functions of these proteins in
recurrent AO would contribute to the development of
therapeutics for the prevention or treatment of this
disease.
Signaling pathways associated with tumor development
in recurrent AO
Recent studies claimed that growth factor signaling is in-
volved in tumorigenesis and the development of malig-
nancy (Lee 2001). EGF signaling is well known to be
involved in the autonomous growth of cancer cells
(Normanno et al. 2001), and FGF signaling plays a pivotal
role in cancer development (Cao et al. 2011). Wnt and
Notch signaling are also associated with tumor develop-
ment (Allenspach et al. 2002; Paul 2000). Therefore, we
investigate whether the identified proteins is involved in
various signaling pathway. The results showed that EGF
signaling is highly associated with recurrent AO compared
to other signaling pathways (Figure 3). This is in agree-
ment with a previous report showing that amplification of
EGFR, which permits evasion of cancer cell death, has
been observed in cases of recurrent AO that develop re-
sistance to treatment (Paul 2000). Additionally, Wnt and
Notch signaling were also associated with recurrent AO.
Further studies regarding the role of Wnt and Notch sig-
naling during the development of AO recurrence will be
necessary.
Proteins related to EGFR in recurrent AO
Based on the fact that EGF signaling is highly related to
recurrent AO (Figure 3) and activation of EGFR is re-
sponsible for the resistance of recurrent AO to treat-
ment, novel regulators or effectors that mediate EGFR
signaling in recurrent AO were sought. EGFR signaling
plays roles in cell proliferation, angiogenesis, and inhib-
ition of apoptosis processes that are essential for cancerdevelopment (Normanno et al. 2001). By additional bio-
informatics analysis of the identified proteins identified
using IPA tool, we indeed found that 15 proteins are
closely associated with EGFR (Figure 4 and Additional
file 1: Table S7), implying that these proteins may play
an important role in the development of recurrent AO.
Conclusion
In this study, we identified proteins significantly expressed
in recurrent AO. Extensive bioinformatics analysis re-
vealed that these proteins are involved in biological pro-
cesses and signaling pathways that are associated with the
development of recurrent AO. Cells in recurrent AO are
highly resistant to apoptosis and actively proliferating.
Analysis of signaling pathway enrichment also showed
that EGF signaling is active in recurrent AO. This is the
first analysis to identify and characterize the proteins asso-
ciated with recurrent AO. Further studies, investigating
the role of these identified proteins in recurrent AO will
contribute to a more thorough understanding of the mo-
lecular mechanisms that mediate the development of this
disease.
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